CLDX
Price
$19.57
Change
+$0.14 (+0.72%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
1.3B
6 days until earnings call
KNSA
Price
$20.56
Change
-$0.32 (-1.53%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
1.49B
11 days until earnings call
Ad is loading...

CLDX vs KNSA

Header iconCLDX vs KNSA Comparison
Open Charts CLDX vs KNSABanner chart's image
Celldex Therapeutics
Price$19.57
Change+$0.14 (+0.72%)
Volume$11.93K
Capitalization1.3B
Kiniksa Pharmaceuticals International
Price$20.56
Change-$0.32 (-1.53%)
Volume$6.68K
Capitalization1.49B
CLDX vs KNSA Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. KNSA commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Buy and KNSA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (CLDX: $19.58 vs. KNSA: $20.56)
Brand notoriety: CLDX and KNSA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 57% vs. KNSA: 52%
Market capitalization -- CLDX: $1.3B vs. KNSA: $1.49B
CLDX [@Biotechnology] is valued at $1.3B. KNSA’s [@Biotechnology] market capitalization is $1.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileKNSA’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • KNSA’s FA Score: 1 green, 4 red.
According to our system of comparison, KNSA is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 5 TA indicator(s) are bullish while KNSA’s TA Score has 5 bullish TA indicator(s).

  • CLDX’s TA Score: 5 bullish, 3 bearish.
  • KNSA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than KNSA.

Price Growth

CLDX (@Biotechnology) experienced а +6.99% price change this week, while KNSA (@Biotechnology) price change was +1.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

CLDX is expected to report earnings on Aug 07, 2025.

KNSA is expected to report earnings on Jul 29, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNSA($1.49B) has a higher market cap than CLDX($1.3B). KNSA YTD gains are higher at: 3.943 vs. CLDX (-23.091). KNSA has higher annual earnings (EBITDA): -43.92M vs. CLDX (-191.9M). CLDX has more cash in the bank: 725M vs. KNSA (244M). CLDX has less debt than KNSA: CLDX (3.81M) vs KNSA (9.86M). KNSA has higher revenues than CLDX: KNSA (423M) vs CLDX (7.02M).
CLDXKNSACLDX / KNSA
Capitalization1.3B1.49B87%
EBITDA-191.9M-43.92M437%
Gain YTD-23.0913.943-586%
P/E RatioN/A164.54-
Revenue7.02M423M2%
Total Cash725M244M297%
Total Debt3.81M9.86M39%
FUNDAMENTALS RATINGS
CLDX vs KNSA: Fundamental Ratings
CLDX
KNSA
OUTLOOK RATING
1..100
1053
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
85
Overvalued
PROFIT vs RISK RATING
1..100
6362
SMR RATING
1..100
9391
PRICE GROWTH RATING
1..100
8160
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (59) in the Biotechnology industry is in the same range as KNSA (85) in the Pharmaceuticals Major industry. This means that CLDX’s stock grew similarly to KNSA’s over the last 12 months.

KNSA's Profit vs Risk Rating (62) in the Pharmaceuticals Major industry is in the same range as CLDX (63) in the Biotechnology industry. This means that KNSA’s stock grew similarly to CLDX’s over the last 12 months.

KNSA's SMR Rating (91) in the Pharmaceuticals Major industry is in the same range as CLDX (93) in the Biotechnology industry. This means that KNSA’s stock grew similarly to CLDX’s over the last 12 months.

KNSA's Price Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as CLDX (81) in the Biotechnology industry. This means that KNSA’s stock grew similarly to CLDX’s over the last 12 months.

KNSA's P/E Growth Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for CLDX (100) in the Biotechnology industry. This means that KNSA’s stock grew significantly faster than CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXKNSA
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 10 days ago
75%
Declines
ODDS (%)
Bearish Trend 17 days ago
80%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMIRX19.12N/A
N/A
Franklin International Equity R
HDGIX31.41N/A
N/A
Hartford Dividend and Growth I
STDFX35.64N/A
N/A
Allspring Large Cap Growth Admin
MIEDX8.47N/A
N/A
MassMutual International Eq R5
QCLGX21.46N/A
N/A
Federated Hermes MDT Large Cap Growth C

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+0.23%
BEAM - CLDX
51%
Loosely correlated
+3.87%
DNLI - CLDX
51%
Loosely correlated
+1.85%
KYMR - CLDX
49%
Loosely correlated
+6.56%
NTLA - CLDX
48%
Loosely correlated
-2.65%
RVMD - CLDX
47%
Loosely correlated
+1.57%
More

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
-1.53%
BEAM - KNSA
40%
Loosely correlated
+1.51%
ABVC - KNSA
40%
Loosely correlated
+4.00%
IOVA - KNSA
38%
Loosely correlated
+5.33%
RGNX - KNSA
38%
Loosely correlated
+3.72%
CLDX - KNSA
37%
Loosely correlated
+0.77%
More